Agilent Technologies Introduces Microarray Scanner Offering Greater Sensitivity, Streamlined Workflow
Complete the form below to unlock access to ALL audio articles.
Agilent Technologies Inc. has introduced the SureScan Microarray Scanner, the latest innovation in scanner technology and the foundation of Agilent’s complete microarray solution for both gene expression and CGH/cytogenetics research applications.
The new SureScan system delivers the highest sensitivity, widest dynamic range and exceptional resolution, providing researchers with the greatest degree of confidence in their microarray results.
In addition, the manufacturing process used on the SureScan Microarray Scanner is ISO 13485 certified, demonstrating Agilent’s commitment in assuring controlled processes.
The SureScan system offers a streamlined workflow, allowing researchers to continuously load microarray slides while the instrument is operating. With the system’s random scanning capability, they can also reprioritize and rearrange the scan queue order at any point during the operation.
Raw image data is automatically loaded into Agilent Feature Extraction software, eliminating manual transfer.
The compact Agilent SureScan Microarray Scanner (16.5 in. high, 17 in. wide and 26 in. deep) conserves bench space. The system also combines a newly designed slide cover and a built-in ozone barrier system to minimize dye signal degradation, protecting valuable samples.
Extremely sensitive results are achieved by the unique dynamic autofocus mechanism in conjunction with a detection limit of as low as 0.01 fluorophores per square micron. These enable users to capture quality data from samples with both low and high signals.
“Researchers can be confident that the new SureScan system will deliver consistently good microarray results for many years to come,” said Robert Schueren, Agilent vice president and general manager, Genomics.
Schueren continued, “With our market-leading portfolio of microarrays, custom microarrays, reagents and software, our customers can invest in one platform knowing that it will fit a wide range of research needs.”